Feed BIIB
BI

Biogen BIIB · NASDAQ

$250.69 -1.24% (-$3.15)

Market cap
$37.5B
Enterprise value
$44.6B
P/E
44.9x
Forward P/E
20.1x
PEG
-
P/S
3.8x
P/FCF
12.6x
EV/EBITDA
26.7x
ROIC
4.3%
Bruto marža
67.7%
Neto marža
8.4%
Dividend yield
-
Payout ratio
-
Neto dolg/EBITDA
4.2x
Beta
0.17
Free float
99.2%

O podjetju

Biogen Inc. (BIIB) is an American biotechnology company specializing in the research, development, and production of therapies for neurological and neurodegenerative diseases. With a portfolio of products focused on treating multiple sclerosis, Alzheimer's disease, and other neurological disorders, Biogen is one of the leading players in the neurology field. The company is known for its emphasis on scientific research and innovation, enabling it to bring groundbreaking treatment options to patients with serious health conditions. Biogen also collaborates with academic institutions and other pharmaceutical companies to expand its research and development capabilities. Biogen Inc. (BIIB) shares could be suitable for investors looking for opportunities in the biotechnology sector with a focus on neurology and neurodegenerative disease research.

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Christopher A. Viehbacher

Employees

7,500

Headquarters

Cambridge

Vrednotenje

Je današnja cena primerna?

Rast in ocene

Ali podjetje raste in kaj sledi?

Donosnost in kakovost

Koliko prihodkov ostane in kako dobro podjetje uporablja kapital?

Finančno zdravje

Ali zmore svoj dolg?

Kapital in dividende

Kaj podjetje počne z zasluženim denarjem?

Analitiki

Kaj menijo strokovnjaki in ali se to spreminja?

Lastniki in insajderji

Kdo ima delnice in kaj počne vodstvo?

Segmenti

Kateri del podjetja raste?

Primerjava s konkurenco

Kako se primerja s podobnimi podjetji?

Cena in tveganje

Kako se delnica obnaša?

Izkazi

Vse številke

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe.